StockNews.AI
MRK
StockNews.AI
68 days

Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs

1. Merck Animal Health received a positive opinion for NUMELVI™ for dogs. 2. NUMELVI™ will be the only second-generation JAK inhibitor for animal treatment.

2m saved
Insight
Article

FAQ

Why Bullish?

The positive opinion for NUMELVI™ enhances Merck's product portfolio and market competitiveness. Historical approvals have often led to stock price increases in biopharma firms.

How important is it?

The news represents a significant product approval that may drive sales and investor confidence.

Why Short Term?

The approval could lead to immediate revenue generation and market presence expansion in veterinary medicine.

Related Companies

ABTPFEVSCO
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that the European Medicines Agency's Committee for Veterinary Medicinal Products (CVMP) issued a positive opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs. NUMELVI, a once-daily, first-line treatment, will be the only second-generation Janus kinase (JAK) inhibitor indicated for the treatmen.

Related News